Patent · US Active

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

US9476047B2 · kind B2 · utility

1Cited by

1References

13Claims

0Family size

Assignee

Arrowhead Pharmaceuticals, Inc. · US

Inventors

Jon E. Chatterton · Fort Worth, US
Abbot F. Clark · Arlington, US
Martin B. Wax · Westlake, US

Key dates

Filing date	Sep 21, 2015
Grant date	Oct 25, 2016
Priority date	—
Expiry date	Sep 21, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.